SWK Holdings Corp Q1 FY2024 earnings call

• Finance segment grew revenue 24% Y/Y to $11.5 million, with gross finance receivables up 10.3% to $274.5 million, effective yield 14.2%, realized yield 16.3%, and remained profitable despite a $6 million loan impairment.
• Enteris division signed an exclusive option and asset purchase agreement with a strategic partner, reducing operating burn and providing opportunities for new business.
• Conducted a share repurchase program, buying back 58,298 shares at $1 million during the quarter and an additional 19,000 shares post-quarter close.
• Book value per share was $22.46 at March 31, 2024, a 5% increase from the prior year, and non-GAAP tangible financing book value per share was $19.69, a 17% increase Y/Y.

The Finance segment saw a 24% year-over-year increase in revenue to $11.5 million, with gross finance receivables portfolio growing 10.3% Y/Y to $274.5 million, an effective yield of 14.2% and realized yield of 16.3%. The Finance segment contributed significantly to the overall results. The Enteris division signed an exclusive option and asset purchase agreement with a strategic partner, receiving a low single-digit million-dollar option fee in April, with guaranteed revenue payments expected in the third quarter.

• Prioritize selectively closing commercial stage life science loan and royalty transactions that fit underwriting criteria.
• Work with nonaccrual borrower partners to realize positive outcomes.
• Explore paths for additional capital and return capital to shareholders via share buyback program.

• Impairment of $6 million on the Trio loan due to a restructuring, with a U.K. borrower involved, and need for a deep dive to understand dynamics.
• Increased competition in certain pockets of the life science finance market, with competitors focusing on large sponsor-backed opportunities.

Q: Could you touch on the impairment and lending capacity?

A: The impairment was on the Trio loan, a U.K. borrower, with restructuring ongoing; lending capacity is around $45 million to $50 million with undrawn revolver and cash, and $200 million of proposals submitted Y/Y with $60 million outstanding.

Q: Has any portfolio company accessed equity markets?

A: Some private and one public company have raised capital recently, which is good for portfolio companies but modestly challenges originating new loans.

Q: Discussion about Enteris and Unigene history?

A: SWK owns Enteris, which was purchased with hopes of big deals like Unigene's past potential, but execution didn't go as hoped; still efforts ongoing but window for monetizing IP not as wide as before, with Peptelligence technology being strong but challenging to get royalties for